The supply of a medicinal product without a marketing authorisation under national provisional permissions of use does not generally prevent an SPC.
The scope of protection of an SPC for a virus may be broader than the specific virus strain mentioned in the marketing authorization.
Today, the EFTA Court ruled on two important SPC issues